RxDoctor Payments Data

Lana Evans, NP

Family · Nappanee, INNPI 1356770267

Payments from drug & device makers

$5,770in general payments, 2019–2025

Across 354 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$613
  • Boehringer Ingelheim$523
  • Novo Nordisk$520
  • Pfizer$430
  • GSK$414
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$5,62798%
  • Education$190%
  • Other$1252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,770 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$42,133
Medicare patients
176
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$55,571
FarxigaDapagliflozin Propanediol26$29,981
JardianceEmpagliflozin13$22,348
OzempicSemaglutide20$17,702
JanuviaSitagliptin Phosphate12$12,894
XareltoRivaroxaban16$11,672
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,090
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,160
Levothyroxine Sodium144$1,299
Atorvastatin Calcium138$834
Gabapentin59$741
Venlafaxine Hcl ErVenlafaxine Hcl30$678
Duloxetine Hcl43$659
Albuterol Sulfate HfaAlbuterol Sulfate23$619
SynthroidLevothyroxine Sodium18$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$286$55,57149 claims
AstraZenecaFarxiga$613$29,98126 claims
Boehringer IngelheimJardiance$523$22,34813 claims
Novo NordiskOzempic$520$17,70220 claims
MerckJanuvia$30$12,89412 claims
Johnson & JohnsonXarelto$108$11,67216 claims
GSKTrelegy Ellipta$414$10,09016 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$1,299144 claims
AbbVieSynthroid$1,078$60918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.

Other family in Nappanee

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →